Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.
Anhydrous enol oxaloacetate
COVID fatigue
Chronic fatigue syndrome
Long COVID
ME/CFS
ME/CFS clinical
ME/CFS treatment
Oxaloacetate
Post viral fatigue
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
28 06 2022
28 06 2022
Historique:
received:
20
05
2022
accepted:
15
06
2022
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
1
7
2022
Statut:
epublish
Résumé
There is no approved pharmaceutical intervention for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS). Fatigue in these patients can last for decades. Long COVID may continue to ME/CFS, and currently, it is estimated that up to 20 million Americans have significant symptoms after COVID, and the most common symptom is fatigue. Anhydrous Enol-Oxaloacetate, (AEO) a nutritional supplement, has been anecdotally reported to relieve physical and mental fatigue and is dimished in ME/CFS patients. Here, we examine the use of higher dosage AEO as a medical food to relieve pathological fatigue. ME/CFS and Long-COVID patients were enrolled in an open label dose escalating "Proof of Concept" non-randomized controlled clinical trial with 500 mg AEO capsules. Control was provided by a historical ME/CFS fatigue trial and supporting meta-analysis study, which showed average improvement with oral placebo using the Chalder Scale of 5.9% improvement from baseline. At baseline, 73.7% of the ME/CFS patients were women, average age was 47 and length of ME/CFS from diagnosis was 8.9 years. The Long-COVID patients were a random group that responded to social media advertising (Face Book) with symptoms for at least 6 months. ME/CFS patients were given separate doses of 500 mg BID (N = 23), 1,000 mg BID (N = 29) and 1000 mg TID (N = 24) AEO for six weeks. Long COVID patients were given 500 mg AEO BID (N = 22) and 1000 mg AEO (N = 21), again over a six-week period. The main outcome measure was to compare baseline scoring with results at 6 weeks with the Chalder Fatigue Score (Likert Scoring) versus historical placebo. The hypothesis being tested was formulated prior to data collection. 76 ME/CFS patients (73.7% women, median age of 47) showed an average reduction in fatigue at 6 weeks as measured by the "Chalder Fatigue Questionnaire" of 22.5% to 27.9% from baseline (P < 0.005) (Likert scoring). Both physical and mental fatigue were significantly improved over baseline and historical placebo. Fatigue amelioration in ME/CFS patients increased in a dose dependent manner from 21.7% for 500 mg BID to 27.6% for 1000 mg Oxaloacetate BID to 33.3% for 1000 mg TID. Long COVID patients' fatigue was significantly reduced by up to 46.8% in 6-weeks. Significant reductions in physical and metal fatigue for ME/CFS and Long-COVID patients were seen after 6 weeks of treatment. As there has been little progress in providing fatigue relief for the millions of ME/CFS and Long COVID patients, anhydrous enol oxaloacetate may bridge this important medical need. Further study of oxaloacetate supplementation for the treatment of ME/CFS and Long COVID is warranted. Trial Registration https://clinicaltrials.gov/ct2/show/NCT04592354 Registered October 19, 2020. 1,000 mg BID Normalized Fatigue Data for Baseline, 2-weeks and 6-weeks evaluated by 3 Validated Fatigue Scoring Questionnaires.
Sections du résumé
BACKGROUND
There is no approved pharmaceutical intervention for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS). Fatigue in these patients can last for decades. Long COVID may continue to ME/CFS, and currently, it is estimated that up to 20 million Americans have significant symptoms after COVID, and the most common symptom is fatigue. Anhydrous Enol-Oxaloacetate, (AEO) a nutritional supplement, has been anecdotally reported to relieve physical and mental fatigue and is dimished in ME/CFS patients. Here, we examine the use of higher dosage AEO as a medical food to relieve pathological fatigue.
METHODS
ME/CFS and Long-COVID patients were enrolled in an open label dose escalating "Proof of Concept" non-randomized controlled clinical trial with 500 mg AEO capsules. Control was provided by a historical ME/CFS fatigue trial and supporting meta-analysis study, which showed average improvement with oral placebo using the Chalder Scale of 5.9% improvement from baseline. At baseline, 73.7% of the ME/CFS patients were women, average age was 47 and length of ME/CFS from diagnosis was 8.9 years. The Long-COVID patients were a random group that responded to social media advertising (Face Book) with symptoms for at least 6 months. ME/CFS patients were given separate doses of 500 mg BID (N = 23), 1,000 mg BID (N = 29) and 1000 mg TID (N = 24) AEO for six weeks. Long COVID patients were given 500 mg AEO BID (N = 22) and 1000 mg AEO (N = 21), again over a six-week period. The main outcome measure was to compare baseline scoring with results at 6 weeks with the Chalder Fatigue Score (Likert Scoring) versus historical placebo. The hypothesis being tested was formulated prior to data collection.
RESULTS
76 ME/CFS patients (73.7% women, median age of 47) showed an average reduction in fatigue at 6 weeks as measured by the "Chalder Fatigue Questionnaire" of 22.5% to 27.9% from baseline (P < 0.005) (Likert scoring). Both physical and mental fatigue were significantly improved over baseline and historical placebo. Fatigue amelioration in ME/CFS patients increased in a dose dependent manner from 21.7% for 500 mg BID to 27.6% for 1000 mg Oxaloacetate BID to 33.3% for 1000 mg TID. Long COVID patients' fatigue was significantly reduced by up to 46.8% in 6-weeks.
CONCLUSIONS
Significant reductions in physical and metal fatigue for ME/CFS and Long-COVID patients were seen after 6 weeks of treatment. As there has been little progress in providing fatigue relief for the millions of ME/CFS and Long COVID patients, anhydrous enol oxaloacetate may bridge this important medical need. Further study of oxaloacetate supplementation for the treatment of ME/CFS and Long COVID is warranted. Trial Registration https://clinicaltrials.gov/ct2/show/NCT04592354 Registered October 19, 2020. 1,000 mg BID Normalized Fatigue Data for Baseline, 2-weeks and 6-weeks evaluated by 3 Validated Fatigue Scoring Questionnaires.
Identifiants
pubmed: 35764955
doi: 10.1186/s12967-022-03488-3
pii: 10.1186/s12967-022-03488-3
pmc: PMC9238249
doi:
Substances chimiques
Oxaloacetic Acid
2F399MM81J
Banques de données
ClinicalTrials.gov
['NCT04592354']
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
295Informations de copyright
© 2022. The Author(s).
Références
Evans WJ, Lambert CP. Physiological basis of fatigue. Am J Phys Med Rehabil. 2007;86(1 Suppl):S29-46.
doi: 10.1097/PHM.0b013e31802ba53c
pubmed: 17370370
Lock AM, Bonetti DL, Campbell ADK. The psychological and physiological health effects of fatigue. Occup Med (Lond). 2018;68(8):502–11.
doi: 10.1093/occmed/kqy109
pubmed: 30445654
Barnett R. Fatigue. Lancet. 2005;366(9479):21.
doi: 10.1016/S0140-6736(05)66809-2
pubmed: 15993215
Wan JJ, Qin Z, Wang PY, et al. Muscle fatigue: general understanding and treatment. Exp Mol Med. 2017;49(10): e384.
doi: 10.1038/emm.2017.194
pubmed: 28983090
pmcid: 5668469
Pennisi M, Malaguarnera G, Di Bartolo G, et al. Decrease in Serum Vitamin D Level of Older Patients with Fatigue. Nutrients. 2019;11(10):2531.
doi: 10.3390/nu11102531
pubmed: 31635199
pmcid: 6836014
Naviaux RK, Naviaux JC, Li K, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci USA. 2016;113(37):E5472-5480.
doi: 10.1073/pnas.1607571113
pubmed: 27573827
pmcid: 5027464
Paul BD, Lemle MD, Komaroff AL, et al. Redox imbalance links COVID-19 and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Proc Natl Acad Sci USA. 2021;118(34):e2024358118.
doi: 10.1073/pnas.2024358118
pubmed: 34400495
pmcid: 8403932
Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). 2020;7: 606824.
doi: 10.3389/fmed.2020.606824
pubmed: 33537329
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.
doi: 10.1126/science.123.3191.309
pubmed: 13298683
Kornberg MD. The immunologic Warburg effect: Evidence and therapeutic opportunities in autoimmunity. Wiley Interdiscip Rev Syst Biol Med. 2020;12(5): e1486.
doi: 10.1002/wsbm.1486
pubmed: 32105390
pmcid: 7507184
Icard P, Lincet H, Wu Z, et al. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie. 2020;180:169–77.
doi: 10.1016/j.biochi.2020.11.010
pubmed: 33189832
pmcid: 7659517
Lawson N, Hsieh CH, March D, et al. Elevated energy production in chronic fatigue syndrome patients. J Nat Sci. 2016;2(10):e221.
pubmed: 27747291
pmcid: 5065105
Graham T, Sjogaard G, Lollgen H, et al. NAD in muscle of man at rest and during exercise. Pflugers Arch. 1978;376(1):35–9.
doi: 10.1007/BF00585245
pubmed: 212709
Sahlin K, Katz A, Henriksson J. Redox state and lactate accumulation in human skeletal muscle during dynamic exercise. Biochem J. 1987;245(2):551–6.
doi: 10.1042/bj2450551
pubmed: 3663177
pmcid: 1148157
Sweetman E, Kleffmann T, Edgar C, et al. A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J Transl Med. 2020;18(1):365.
doi: 10.1186/s12967-020-02533-3
pubmed: 32972442
pmcid: 7512220
Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–32.
doi: 10.1016/j.ijid.2020.09.016
pubmed: 32920235
pmcid: 7529115
Gupta SC, Kim JH, Kannappan R, et al. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood). 2011;236(6):658–71.
doi: 10.1258/ebm.2011.011028
pubmed: 21565893
Bower JE, Ganz PA, Irwin MR, et al. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun. 2011;25(1):147–50.
doi: 10.1016/j.bbi.2010.09.010
pubmed: 20854893
Morris G, Maes M. Increased nuclear factor-kappaB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses. 2012;79(5):607–13.
doi: 10.1016/j.mehy.2012.07.034
pubmed: 22951418
Filler K, Lyon D, Bennett J, et al. Association of mitochondrial dysfunction and fatigue: a review of the literature. BBA Clin. 2014;1:12–23.
doi: 10.1016/j.bbacli.2014.04.001
pubmed: 25147756
pmcid: 4136529
Brown AE, Jones DE, Walker M, et al. Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome. PLoS ONE. 2015;10(4): e0122982.
doi: 10.1371/journal.pone.0122982
pubmed: 25836975
pmcid: 4383615
Fisicaro F, Di Napoli M, Liberto A, et al. Neurological sequelae in patients with COVID-19: a histopathological perspective. Int J Environ Res Public Health. 2021;18(4):1415.
doi: 10.3390/ijerph18041415
pubmed: 33546463
pmcid: 7913756
Nogueira L. Acute oxaloacetate exposure enhances resistance to fatigue in in vitro mouse soleus muscle. FASEB J. 2011. https://doi.org/10.1096/fasebj.25.1_supplement.1104.5 .
doi: 10.1096/fasebj.25.1_supplement.1104.5
Germain A, Ruppert D, Levine SM, et al. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. 2017;13(2):371–9.
doi: 10.1039/C6MB00600K
pubmed: 28059425
pmcid: 5365380
Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953–9.
doi: 10.7326/0003-4819-121-12-199412150-00009
pubmed: 7978722
Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–53.
doi: 10.1016/0022-3999(93)90081-P
pubmed: 8463991
Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.
doi: 10.1001/archneur.1989.00520460115022
pubmed: 2803071
Yang M, Keller S, Lin JS. Psychometric properties of the PROMIS((R)) Fatigue Short Form 7a among adults with myalgic encephalomyelitis/chronic fatigue syndrome. Qual Life Res. 2019;28(12):3375–84.
doi: 10.1007/s11136-019-02289-4
pubmed: 31506915
Cho HJ, Hotopf M, Wessely S. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom Med. 2005;67(2):301–13.
doi: 10.1097/01.psy.0000156969.76986.e0
pubmed: 15784798
Ijare O, Conway D, Cash A, et al. CBMT-49. oxaloacetate alters glucose metabolism in glioblastoma 13C isotopomer study. Neuro-Oncology. 2019;21(Supplement_6):vi43–4.
doi: 10.1093/neuonc/noz175.171
pmcid: 6847071
Morris G, Maes M. Oxidative and Nitrosative Stress and immune-inflammatory pathways in patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). Curr Neuropharmacol. 2014;12(2):168–85.
doi: 10.2174/1570159X11666131120224653
pubmed: 24669210
pmcid: 3964747
Wilkins HM, Harris JL, Carl SM, et al. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum Mol Genet. 2014;23(24):6528–41.
doi: 10.1093/hmg/ddu371
pubmed: 25027327
pmcid: 4271074
Williams DS, Cash A, Hamadani L, et al. Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway. Aging Cell. 2009;8(6):765–8.
doi: 10.1111/j.1474-9726.2009.00527.x
pubmed: 19793063
Haslam JM, Krebs HA. The permeability of mitochondria to oxaloacetate and malate. Biochem J. 1968;107(5):659–67.
doi: 10.1042/bj1070659
pubmed: 16742587
pmcid: 1198718
Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med. 2012;5(3):208–20.
pubmed: 22837795
pmcid: 3403556
Wilkins HM, Koppel S, Carl SM, et al. Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. J Neurochem. 2016. https://doi.org/10.1111/jnc.13545 .
doi: 10.1111/jnc.13545
pubmed: 26811028
pmcid: 5482267
Brown AE, Dibnah B, Fisher E, et al. Pharmacological activation of AMPK and glucose uptake in cultured human skeletal muscle cells from patients with ME/CFS. 2018. Biosci Rep. https://doi.org/10.1042/BSR20180242 .
Yoshikawa K. Studies on the anti-diabetic effect of sodium oxaloacetate. Tohoku J Exp Med. 1968;96(2):127–41.
doi: 10.1620/tjem.96.127
pubmed: 4884771
Vidoni ED, Choi IY, Lee P, et al. Safety and target engagement profile of two oxaloacetate doses in Alzheimer’s patients. Alzheimers Dement. 2020. https://doi.org/10.1002/alz.12156 .
doi: 10.1002/alz.12156
pubmed: 32715609
pmcid: 8084114
Desagher S, Glowinski J, Premont J. Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J Neurosci. 1997;17(23):9060–7.
doi: 10.1523/JNEUROSCI.17-23-09060.1997
pubmed: 9364052
pmcid: 6573585
Puntel RL, Nogueira CW, Rocha JB. Krebs cycle intermediates modulate thiobarbituric acid reactive species (TBARS) production in rat brain in vitro. Neurochem Res. 2005;30(2):225–35.
doi: 10.1007/s11064-004-2445-7
pubmed: 15895826
Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol Lett. 2003;143(2):115–22.
doi: 10.1016/S0378-4274(03)00114-0
pubmed: 12749815